

**MSD SHARP & DOHME GMBH /  
Merck & Co., Inc**

Dr. Manfred Horst

3 Avenue Hoche  
75114 Paris / France  
Tel: +33 1 4754 8858  
Email: Manfred.horst@merck.com  
www.merck.com

**Company Overview**

With a steady focus on innovation and sound science, Merck has worked for more than 150 years to deliver vaccines, medications, and consumer and animal health products that save and improve the lives of millions around the world. In Germany Merck is known as MSD SHARP & DOHME GMBH.

Our passion for medicine is evident in the breadth of our product line. Merck offers therapies for the treatment of cardiovascular disease, high blood pressure, elevated cholesterol levels, diabetes, cancer, benign prostatic hypertrophy, asthma and allergies, arthritis, pain, migraine, glaucoma, osteoporosis, women's health, infectious diseases (antibiotic, antifungal, and antiviral agents) and vaccines to prevent childhood diseases, human papilloma virus, rotavirus, shingles, and hepatitis A, B and C. Our worldwide product sales in 2011 were \$48 billion.

Our focus will remain on advancing and augmenting our pipeline, which we believe to be one of the most promising in our industry. Greater scientific discoveries – from our labs and through our collaborations with partners – will allow us to bring new life-changing therapies to patients and a strong financial performance to shareholders.

**Embracing Partnerships**

Merck has hundreds of successful collaborations with companies, institutions, academics, and other organizations around the world who share our passion for science. In fact, 55% of Merck's 2011 human health sales were attributable to these alliance products and patents — including some of our biggest blockbusters. In 2011, Merck executed 52 significant transactions and entered into many smaller licensing deals and research collaborations.

These transactions span a range of therapeutic areas, deal types and geographies.

We welcome partnerships in a range of therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. We are interested in partnerships at all stages of development -- from earliest discovery, preclinical through late-stage development, as well as for registered and/or marketed products for regional commercialization partnerships.

A comprehensive list of our specific partnering interests is available at [www.merck.com/licensing](http://www.merck.com/licensing) and includes: atherosclerosis, cardiovascular disease, diabetes, endocrinology, infectious diseases, neurosciences, ophthalmology, oncology, respiratory, immunology, vaccines and biologics. We look to integrate key product enablers (e.g., biomarkers, diagnostics, devices, drug delivery and information) into the development of our products. For Phase III-ready candidates and beyond, Merck is interested in any therapeutic area. We also are seeking regional commercial deals for registered or marketed products.

When you partner with Merck, you will have world-class research and development, regulatory, manufacturing, marketing, and sales resources to ensure commercial success for your discovery. Let's explore how we can combine our strengths with yours, and share our successes together.